Circadian telomerase activity and DNA synthesis for timing peptide administration

Peptides

Volumn 24, Issue 3, 2003, Pages 363-369

  Qu, Yi ^a   Wang, Zhengrong ^a   Huang, Xiang ^b   Wan, Chaomin ^a   Yang, Chun Lei ^a   Liu, Bailin ^a   Cornelissen, Germaine ^c   Halberg, Franz ^c  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cell cycle; Circadian rhythm; DNA synthesis; Hepatic carcinoma; Nude mice; Telomerase activity

Indexed keywords

CELL DNA; TELOMERASE; TELOMERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CHRONOTHERAPY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DARKNESS; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; LIGHT; LIVER CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SAMPLING; TIME;

MUS MUSCULUS;

EID: 0038742950     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(03)00050-0     Document Type: Article

References (24)

1. Bingham C., Arbogast B., Cornélissen Guillaume G., Lee J.K., Halberg F. Inferential statistical methods for estimating and comparing cosinor parameters. Chronobiologia. 9:1982;397-439.
2. Cornélissen G, Halberg F. Introduction to chronobiology. Medtronic Chronobiology Seminar #7; 1994 April. p. 52 (Library of Congress Catalog Card #94-060580; URL [accessed 1994] http://www.msi.umn.edu/∼halberg/ ).
3. Cornélissen G, Halberg F. Chronomedicine. In: Armitage P, Colton T, Editors-in-Chief. Encyclopedia of biostatistics, vol. 1. Chichester, UK: Wiley; 1998. p. 642-9.
4. Greider C.W., Blackbum E.H. Telomeres, telomerase and cancer. Sci. Am. 274(February):1996;92-97.
5. Halberg F. Chronobiology: methodological problems. Acta Medica Romana. 18:1980;399-440.
6. Halberg F. Quo vadis basic and clinical chronobiology: promise for health maintenance. Am. J. Anat. 168:1983;543-594.
7. Halberg F., Barnum C.P., Silber R.H., Bittner J.J. 24-h rhythms at several levels of integration in mice on different lighting regimens. Proc. Soc. Exp. Biol. (N. Y.). 97:1958;897-900.
8. Halberg F, Gupta BD, Haus E, Halberg E, Deka AC, Nelson W, et al. Steps toward a cancer chronopolytherapy. In: Proceedings of the Fourteenth International Congress of Therapeutics, Montpellier, France. L'Expansion Scientifique Française 1977;151-96.
9. Halberg F., Lakatua D., Lodeiro C., Garcia L., Hermida R., Ayala D.et al. Chronobiology, growth hormone and healthy and malignant growth. J. Endocrinol. Invest. 12(Suppl 3):1989;41-47.
10. Halberg F., Nelson W., Cornélissen G., Haus E., Scheving L.E., Good R.A. On methods for testing and achieving cancer chronotherapy. Cancer Treatment Rep. 63:1979;1428-1430.
11. Harada K., Yasoshima M., Ozaki S., Sanzen T., Nakanuma Y. PCR and in situ hybridization studies of telomerase subunits in human non-neoplastic livers. J. Pathol. 193:2001;210-217.
12. Holt S.E., Glinsky V.V., Ivanova A.B., Glinsky G.V. Resistance to apoptosis in human cell conferred by telomerase function and telomere stability. Mol. Carcinog. 25(4):1999;241-248.
13. Hsieh H.F., Harn H.J., Chiu S.C., Liu Y.C., Lui W.Y., Ho L.I. Telomerase activity correlates with cell cycle regulators in human hepatocellular carcinoma. Liver. 20:2000;143-151.
14. Ichikura T., Okusa Y., Mochizuki H. Telomerase activity during the cell cycle in gastric cancer cell lines. Nippon Rinsho. 56:1998;1199-1203.
15. Kruk P.A., Orren D.K., Bohr V.A. Telomerase activity is elevated in early phase in hamster cells. Biochem. Biophys. Res. Commun. 233:1997;717-722.
16. Levi F. Cancer chronotherapy. J. Pharm. Pharmacol. 51:1999;891-898.
17. Levi F., Zidani R., Misset J.L. Randomised multi-centre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 350(9079):1997;681-686.
18. Liu B.L., Qu Y., Liu S.Q., Ouyang X.S. Inhibition of telomerase in tumor cells by ribozyme targeting telomerase RNA component. Sci. China (Ser. C). 45:2002;87-95.
19. Nakamura M., Saito H., Ebinuma H., Wakabayashi K., Saito Y., Takagi T.et al. Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor. J. Cell. Physiol. 187:2001;392-401.
20. Ohta K., Kanamaru T., Morita Y., Hayashi Y., Ito H., Yamamoto M. Telomerase activity in hepatocellular carcinoma as a predictor of postoperative recurrence. J. Gastroenterol. 32:1997;791-796.
21. Rensing L., Goedeke K. Circadian rhythm and cell cycle: possible entraining mechanisms. Chronobiologia. 3(1):1976;53-65.
22. Ulmer W., Cornélissen G., Revilla M., Siegelova J., Dusek J., Halberg F. Circadian and circaseptan dependence of the beta-ATP peak of four different cancer cell cultures: implications for chronoradiotherapy. Scripta Medica (Brno). 74:2001;87-92.
23. Vonderheide R.H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 21:2002;674-679.
24. Zhu X., Kumar R., Mandal M., Sharma N., Sharma H.W., Dhingra U.et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. U.S.A. 93:1996;6091-6095.